NewLimit Secures $435M Series C to Advance AI-Driven Epigenetic Reprogramming into Clinical Trials, as IMU and Waypoint Push AI Life Science Platforms Toward Clinical Validation

Last week, globalAI Healthcare Funding Focus Shifts Back to Life Sciences and Specialty Medical Data Infrastructure. NewLimit raised $435 million to advance aging reprogramming therapies into late preclinical stages, while IMU Biosciences, Waypoint Bio, and Ingenix entered the drug development process through immune system decoding, AI-designed cell therapies, and biological reasoning engines, respectively. On the healthcare services side, Novellia, Ilant Health, and MediElaj secured funding for patient-empowered real-world data, AI-supported obesity management, and primary care diagnostic entry points, respectively.

The core change this week is,AI in healthcare is evolving from “model-generated candidate solutions” to a “closed loop of models, data, and clinical validation.” NewLimit and Waypoint Bio share a common approach: they are not satisfied with merely having AI generate more experimental hypotheses. Instead, they integrate machine learning, functional genomics, spatial biology, and clinical development pathways to accelerate the identification of candidates truly ready for human validation. Meanwhile, Novellia and IMU Biosciences demonstrate that the foundation of future competition in AI-driven healthcare remains high-quality, licensable, and interpretable data assets.

• NewLimit

Financing Amount:$435 million

Round:Series C

NewLimit, headquartered in South San Francisco, USA, is a biotechnology company focused on longevity medicine and age-related diseases, founded by Brian Armstrong, Blake Byers, and Jacob Kimmel. On June 2, 2026, NewLimit announced the completion of a $435 million Series C financing round, led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Eli Lilly Ventures, and others, bringing its post-money valuation to approximately $3.1 billion. The company centers its efforts on epigenetic reprogramming, aiming to treat age-related diseases by restoring cells to a younger gene expression state, with its initial flagship program targeting liver-related diseases. NewLimit leverages functional genomics, pooled perturbation screens, and machine learning models to identify payloads capable of restoring cellular youthfulness in large-scale experiments, applying these insights to the design of drug candidates. This funding will support the advancement of its first drug candidate into preparations for human clinical trials, signaling that “AI + longevity medicine” is transitioning from a research vision to a stage closer to actual drug development.

• IMU Biosciences

Financing Amount: Over$53 million

Round:Series A Extension Financing

Headquartered in London, UK, IMU Biosciences is a biotechnology company that deciphers disease mechanisms by leveraging large-scale immune system data. On June 2, 2026, IMU Biosciences announced the completion of an oversubscribed financing round, bringing its total Series A funding to over $53 million. The round was co-led by IQ Capital and Molten Ventures, with participation from British Business Bank, Meltwind, and existing investors. By measuring more than 100 million immune data points from simple blood samples, IMU constructs the world’s largest immune system dataset to understand patient responses to diseases and treatments. Its platform combines deep immune phenotyping with artificial intelligence (AI) to help researchers identify immune states, disease progression, transplant reactions, and response patterns to cancer immunotherapy. The funding will support the expansion of the company’s clinical platform and data infrastructure, as well as advance projects related to stem cell transplantation, solid organ transplantation, and cancer immunotherapy. IMU’s value lies in transforming the immune system from a “complex network that is difficult to observe” into a computable, comparable data layer that informs clinical decision-making.

• Waypoint Bio

Financing Amount:$20 million

Round:Series A

Waypoint Bio, headquartered in New York, USA, is an AI-native cell therapy company that leverages spatial biology, computer vision, and artificial intelligence to design next-generation in vivo CAR-T therapies targeting solid tumors. On June 1, 2026, Waypoint Bio announced the completion of a $20 million Series A financing round, led by Amplify Partners, with participation from General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, and existing investor Hummingbird Ventures. The company’s platform employs spatialized pooled screening to observe the real-world performance of candidate CAR-T constructs within the tumor microenvironment, feeding these spatial readouts back into AI models to identify more promising therapeutic candidates. Its lead program, WAY-103, targets gastric and pancreatic cancers and is scheduled to initiate investigator-initiated clinical trials by the end of 2026. Rather than simply generating a greater volume of cell therapy designs, Waypoint focuses on creating a closed-loop system that integrates AI-driven design, spatial experimental validation, and accelerated clinical pathways to enhance the translational efficiency of cell therapies for solid tumors.

• Novellia

Financing Amount:$18 million

Round:Series A

Novellia, headquartered in New York, USA, is a real-world data platform company centered on patient-authorized data, primarily serving large pharmaceutical companies, research institutions, and patients themselves. On June 2, 2026, Novellia announced the completion of an $18 million Series A financing round, led by Spark Capital, with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing the company’s total funding to $28 million. Novellia’s platform enables patients to access, organize, and control their complete medical history free of charge, and to use this data for medical research and drug development on a voluntary, authorized basis. The company employs AI technology to clean, organize, and interpret health records across hospitals, physicians, and time periods, transforming fragmented patient medical records into real-world data suitable for research. For pharmaceutical companies, such platforms can reduce the costs associated with patient recruitment and the acquisition of real-world evidence; for patients, it returns data sovereignty and opportunities for research participation to individuals.

• Ilant Health

Financing Amount:$15 million

Round:Series A

Ilant Health, headquartered in New York, USA, is a value-based obesity treatment company serving employers and health plans. On June 2, 2026, Ilant Health announced the completion of a $15 million Series A financing round, led by Cornucopian Capital, with participation from naturalX, PeakBridge, Semcap AI, Evidenced, Operator Partners, and existing investors Celtic, LifeX, and AlphaLab, bringing the company’s total funding to over $22 million. Ilant has redefined obesity management from isolated GLP-1 prescriptions or lifestyle advice into a continuum of care encompassing behavioral therapy, pharmacotherapy, nutrition, exercise, stress management, and surgical referrals when necessary. Its AI technology is primarily used to continuously optimize treatment pathways based on clinical, behavioral, and individual response data, helping care teams determine which patients are suitable for medication, which require behavioral interventions, and which need more intensive regimens. Its value lies in shifting obesity treatment from a “one-size-fits-all” approach to more precise, personalized management, while simultaneously helping payers control ineffective or unnecessary expenditures.

• Ingenix

Financing Amount:€13 million

Round:Seed Extension

Headquartered in Warsaw, Poland, Ingenix is an AI and biology company whose core product is the Biological Reasoning Engine for drug discovery. On June 3, 2026, Ingenix announced the completion of a €13 million seed extension round, led by Sofinnova Partners with participation from Inovo VC and OTB VC. Ingenix’s proposed Modality Fusion architecture aims to enable AI to simultaneously understand multiple biological data modalities, integrating genomics, transcriptomics, proteomics, phenotypes, and disease context into a unified reasoning framework. The company states that, in one oncology project, its system completed in minutes the biological reasoning work that had taken its partner years to develop. Ingenix’s goal is not to build a general-purpose question-and-answer tool, but rather to establish AI as a biological reasoning layer in drug discovery, helping research teams faster elucidate disease mechanisms, identify targets, and design subsequent experiments.

• MediElaj

Financing Amount:$100,000

Round:Pre-seed

MediElaj, headquartered in Gurugram, India, is a health technology company focused on preventive healthcare and primary care diagnostics. On June 2, 2026, MediElaj announced the completion of approximately $100,000 in pre-seed financing, sourced from the founders’ friends and family network. The company is building an AI-driven health platform and smart diagnostic kiosks, with a focus on serving underserved areas such as small and medium-sized cities and rural regions where healthcare accessibility is limited. Its product portfolio includes mobile health applications, integrated diagnostic devices, sensors, cloud infrastructure, and AI-assisted initial screening capabilities, designed to provide basic health assessments and early disease risk identification. Although the funding amount is modest, the project represents another direction for AI in healthcare within emerging markets: rather than initially serving large hospitals or pharmaceutical companies, it combines AI, hardware, and remote health services to lower the barrier for grassroots populations to access preliminary health assessments.

[Microsoft: Co-developing cutting-edge AI models for healthcare with Mayo Clinic to enhance clinical reasoning capabilities]

On June 2, 2026, Microsoft and Mayo Clinic announced a partnership to develop cutting-edge AI models tailored for healthcare scenarios. Trained on Mayo Clinic’s medical expertise, de-identified clinical data, research materials, and the experience of physicians and healthcare professionals, the model aims to support clinical reasoning, analysis of complex medical information, treatment decision-making, and more personalized patient care. Mayo Clinic will retain ownership of the model to uphold patient trust, clinical oversight, and responsibility for medical data governance, while Microsoft will provide engineering and deployment capabilities through its cloud-based AI platform.

For the industry, this collaboration marks a shift in the trajectory of large medical models, moving from general health Q&A toward models that are institution-owned, clinically supervised, and specialty-validated. In the past, consumers often regarded generalTreating AI as a "doctor search portal" is inappropriate for high-risk clinical scenarios due to limitations in its training data and undefined liability boundaries. The Mayo Clinic–Microsoft model places healthcare institutions’ data governance and clinical expertise at the core, with technology companies providing models and cloud infrastructure. This approach may serve as an important reference for large hospital systems developing their own proprietary medical AI models in the future.

[Sanofi: Expands Partnership with Owkin to Introduce Agentic AI into Drug Discovery Process]

On June 5, 2026, Sanofi expanded its AI collaboration with Owkin by launching a new agentic AI initiative and securing a five-year license for Owkin’s AI Scientist platform K Pro. The partnership, which began in 2021, initially focused on oncology target identification and patient subgroup analysis, later extending to drug positioning within the immunology pipeline. This new project will further integrate AI agents into Sanofi’s biopharmaceutical R&D workflows, with Owkin leading the development of AI-driven drug discovery agents tailored to Sanofi’s needs.

Such collaborations reflect that large pharmaceutical companies are shifting away from purchasing single-pointAI tools are evolving into AI agent systems customized for internal R&D workflows. Drug development is not a single task but a complex chain comprising target discovery, evidence integration, patient stratification, experimental design, translational medicine, and clinical strategy. The collaboration between Sanofi and Owkin focuses on upgrading AI from an analytical tool to a workflow partner that continuously participates in R&D decision-making, helping research teams identify candidate directions more rapidly, validate biological hypotheses, and adjust pipeline strategies.

Probe AI Healthcare Weekly: H1 Raises $40 Million, Triomics Secures $22 Million in Funding, as AI Healthcare Continues to Penetrate Core Processes of Pharmaceutical Companies and Hospitals [260601]

Probe AI Healthcare Weekly: Commure Raises $70 Million, The Path Secures $14.3 Million, AI Healthcare Moves from Back-Office Operations to Patient-Facing Entry Points [260525]

Probe AI Healthcare Weekly: Isomorphic Labs Raises $2.1 Billion, Forus Secures Over $160 Million, and AI Healthcare Operations Projects Complete Financing Intensively [260518]